455 related articles for article (PubMed ID: 11531262)
21. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
22. Evidence for a critical role of DNA topoisomerase IIalpha in drug sensitivity revealed by inducible antisense RNA in a human leukaemia cell line.
Towatari M; Adachi K; Marunouchi T; Saito H
Br J Haematol; 1998 Jun; 101(3):548-51. PubMed ID: 9633900
[TBL] [Abstract][Full Text] [Related]
23. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
24. Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.
Bhosle J; Kiakos K; Porter AC; Wu J; Makris A; Hartley JA; Hochhauser D
Mol Cancer Ther; 2013 Dec; 12(12):2897-908. PubMed ID: 24092808
[TBL] [Abstract][Full Text] [Related]
25. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
26. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
[TBL] [Abstract][Full Text] [Related]
27. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
Hashimoto S; Chatterjee S; Ranjit GB; Bao C; Ford J; Ganapathi R; Berger SJ; Berger NA
Oncol Res; 1995; 7(7-8):407-16. PubMed ID: 8747604
[TBL] [Abstract][Full Text] [Related]
28. Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.
Kozuki T; Chikamori K; Surleac MD; Micluta MA; Petrescu AJ; Norris EJ; Elson P; Hoeltge GA; Grabowski DR; Porter ACG; Ganapathi RN; Ganapathi MK
Nucleic Acids Res; 2017 Jun; 45(10):5995-6010. PubMed ID: 28472494
[TBL] [Abstract][Full Text] [Related]
29. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
30. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
Ogiso Y; Tomida A; Lei S; Omura S; Tsuruo T
Cancer Res; 2000 May; 60(9):2429-34. PubMed ID: 10811120
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
Satterwhite DJ; White RL; Matsunami N; Neufeld KL
Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401
[TBL] [Abstract][Full Text] [Related]
32. Topoisomerase II-mediated alterations of K562 drug resistant sublines.
Zhou R; Wang Y; Gruber A; Larsson R; Castaños-Vèlez E; Liliemark E
Med Oncol; 1999 Sep; 16(3):191-8. PubMed ID: 10523799
[TBL] [Abstract][Full Text] [Related]
33. Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.
Stacey DW; Hitomi M; Chen G
Mol Cell Biol; 2000 Dec; 20(24):9127-37. PubMed ID: 11094065
[TBL] [Abstract][Full Text] [Related]
34. Decreased topoisomerase IIalpha expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells.
Kobayashi M; Adachi N; Aratani Y; Kikuchi A; Koyama H
Cancer Lett; 2001 May; 166(1):71-7. PubMed ID: 11295289
[TBL] [Abstract][Full Text] [Related]
35. Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.
Whitacre CM; Zborowska E; Gordon NH; Mackay W; Berger NA
Cancer Res; 1997 Apr; 57(8):1425-8. PubMed ID: 9108439
[TBL] [Abstract][Full Text] [Related]
36. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
37. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
Aoyama M; Grabowski DR; Dubyak GR; Constantinou AI; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Biochem J; 1998 Dec; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
[TBL] [Abstract][Full Text] [Related]
38. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
Matsumoto Y; Takano H; Fojo T
Cancer Res; 1997 Nov; 57(22):5086-92. PubMed ID: 9371507
[TBL] [Abstract][Full Text] [Related]
39. DNA topoisomerase IIalpha and -beta expression in human ovarian cancer.
Withoff S; van der Zee AG; de Jong S; Hollema H; Smit EF; Mulder NH; de Vries EG
Br J Cancer; 1999 Feb; 79(5-6):748-53. PubMed ID: 10070864
[TBL] [Abstract][Full Text] [Related]
40. Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity.
Uesaka T; Shono T; Kuga D; Suzuki SO; Niiro H; Miyamoto K; Matsumoto K; Mizoguchi M; Ohta M; Iwaki T; Sasaki T
J Neurooncol; 2007 Sep; 84(2):119-29. PubMed ID: 17361331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
